2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-170397
    ADORA2A/PDE4D-IN-1
    		Inhibitor
    ADORA2A/PDE4D-IN-1 (Compound 9) is a dual inhibitor for adenosine A2a receptor (ADORA2A) and phosphodiesterase 4D (PDE4D). ADORA2A/PDE4D-IN-1 can be used in research of bronchial asthma.
    ADORA2A/PDE4D-IN-1
  • HY-150614
    Autotaxin-IN-6
    		Inhibitor
    Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC50 value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer.
    Autotaxin-IN-6
  • HY-158001
    MHC00188
    		Inhibitor
    MHC00188 is an allosteric inhibitor for Autotaxin (ATX) with an IC50 of 2.53 μM.
    MHC00188
  • HY-90009AS
    Tadalafil-13C2,d3
    		Inhibitor
    Tadalafil-13C2,d3 is 13C and deuterated labeled Tadalafil (HY-90009A). Tadalafil (IC-351) is a PDE5 inhibitor with an IC50 value of 1.8 nM.
    Tadalafil-<sup>13</sup>C<sub>2</sub>,d<sub>3</sub>
  • HY-167715
    Traxanox
    		Inhibitor
    Traxanox is an orally available diuretic that enhances phagocytosis of yeast granules by mouse peritoneal macrophages and rat peritoneal polymorphonuclear leukocytes in vitro. Traxanox inhibits IgE-mediated histamine release and cyclic AMP phosphodiesterase activity.Traxanox exhibits anti-inflammatory activity, as it inhibits the anaphylactoid reaction and reduces pleural fluid accumulation in experimental models of inflammation. Traxanox also demonstrates a synergistic effect when combined with hydrocortisone or indomethacin in suppressing adjuvant arthritis in rats.
    Traxanox
  • HY-W186242
    PDE4-IN-16
    		Inhibitor
    PDE4-IN-16 (compound 27) is a PDE4 inhibitor with an IC50 value of 3.61 μM. PDE4-IN-16 can be used for the research of inflammatory diseases and central nervous system (CNS) disorders involving elevated levels of cytokines.
    PDE4-IN-16
  • HY-121037
    Eggmanone
    		Inhibitor
    Eggmanone (EGM1) is a potent and selective phosphodiesterase 4 (PDE4) antagonist with an IC50 of 72 nM for PDE4D3. Eggmanone shows approximately 40- to 50-fold selective for PDE4D3 over other PDEs. Eggmanone exerts its Hh-inhibitory effects through selective antagonism of PDE4, leading to protein kinase A activation and subsequent Hh blockade.
    Eggmanone
  • HY-18252B
    (R)-Avanafil
    		Inhibitor
    (R)-Avanafil ((R)-TA1790) is a selective PDE5 inhibitor (IC50: 5.2 nM). (R)-Avanafil can be used for research of erectile dysfunction.
    (R)-Avanafil
  • HY-114643
    (Rac)-Tovinontrine
    		Inhibitor
    (Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia.
    (Rac)-Tovinontrine
  • HY-115871A
    (Rac)-PDE4-IN-4
    		Inhibitor
    (Rac)-PDE4-IN-4 is the diastereomer mixture of PDE4-IN-4 (HY-115871). PDE4-IN-4 is a dual M3 (pIC50 = 10.2) antagonist-PDE4 (pIC50 = 8.8) inhibitor for the inhaled research of pulmonary diseases.
    (Rac)-PDE4-IN-4
  • HY-143237
    ATX inhibitor 11
    		Inhibitor
    ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC50 of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research.
    ATX inhibitor 11
  • HY-B0312S1
    Dipyridamole-d16
    		Inhibitor
    Dipyridamole-d16 is the deuterium labeled Dipyridamole. Dipyridamole (Persantine) is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells.
    Dipyridamole-d<sub>16</sub>
  • HY-N3945R
    Glaucine (Standard)
    		Inhibitor
    Glaucine (Standard) is the analytical standard of Glaucine. This product is intended for research and analytical applications. Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 μM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities.
    Glaucine (Standard)
  • HY-123154
    PDE10A-IN-4
    		Inhibitor
    PDE10A-IN-4 (compound 38) is a compound used to inhibit schizophrenia. As a PDE10A inhibitor, it is less effective than placebo in inhibiting acute schizophrenia and does not show antipsychotic effect.
    PDE10A-IN-4
  • HY-153398
    Enpp-1-IN-17
    		Inhibitor
    Enpp-1-IN-17 (example 274) is a potent ENPP1 inhibitor, with the inhibition constants (Ki values) toward cGAMP and ATP hydrolysis of 100 nM-1 μM and > 1 μM, respectively. The selectivity ratio for inhibition of cGAMP hydrolysis versus ATP hydrolysis is >6.4.
    Enpp-1-IN-17
  • HY-128060
    PDE5-IN-42
    		Inhibitor
    PDE5-IN-42 (Compound 42) is a potent and orally active PDE5 inhibitor with an IC50 of 0.04 nM. PDE5-IN-42 maintains selectivity over PDE6 and PDE11.
    PDE5-IN-42
  • HY-114727
    PDE7-IN-4
    PDE7-IN-4 is a phosphodiesterase 7 (PDE7) inhibitor with activity that increases intracellular cyclic adenosine monophosphate (cAMP) levels. PDE7-IN-4 shows potential inhibitory effects in neurotransmission and anti-inflammatory applications. PDE7-IN-4 exerts its biological activity by acting on the cAMP/cAMP response element binding protein (CREB) pathway. The development of PDE7-IN-4 aims to improve its pharmacokinetic characteristics to more effectively target neurodegenerative diseases and other inflammation-related diseases.
    PDE7-IN-4
  • HY-144684
    PDE4-IN-8
    		Inhibitor
    PDE4-IN-8 (Example 5) is a potent PDE4 inhibitor with an IC50 of 0.93 nM for PDE4B2.PDE4-IN-8 has little effect on IL13 (IC50=4.04 nM), IL4 (IC50=36.33 nM), IFNy (IC50=2394 nM).
    PDE4-IN-8
  • HY-18252S
    Avanafil-13C,d3
    		Inhibitor
    Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
    Avanafil-<sup>13</sup>C,d<sub>3</sub>
  • HY-134954
    Palmitoleoyl 3-carbacyclic phosphatidic acid
    		Inhibitor
    Palmitoleoyl 3-carbacyclic phosphatidic acid (3ccPA 16:1) is an intermediately potent inhibitor of autotaxin (ATX) with an IC50 of 620 nM. Palmitoleoyl 3-carbacyclic phosphatidic acid can be used for melanoma research.
    Palmitoleoyl 3-carbacyclic phosphatidic acid
Cat. No. Product Name / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.